These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059 [TBL] [Abstract][Full Text] [Related]
43. Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. Al-Soud YA; Al-Masoudi NA; Hassan HG; De Clercq E; Pannecouque C Acta Pharm; 2007 Dec; 57(4):379-93. PubMed ID: 18165184 [TBL] [Abstract][Full Text] [Related]
44. Brain-derived cells contain a specific binding site for Gp120 which is not the CD4 antigen. Kozlowski MR; Sandler P; Lin PF; Watson A Brain Res; 1991 Jul; 553(2):300-4. PubMed ID: 1933287 [TBL] [Abstract][Full Text] [Related]
45. Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Yao XJ; Wainberg MA; Parniak MA Virology; 1992 Mar; 187(1):56-62. PubMed ID: 1371029 [TBL] [Abstract][Full Text] [Related]
46. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents. Rausch DM; Hwang KM; Padgett M; Voltz AH; Rivas A; Engleman E; Gaston I; McGrath M; Fraser B; Kalyanaraman VS Ann N Y Acad Sci; 1990; 616():125-48. PubMed ID: 2078014 [TBL] [Abstract][Full Text] [Related]
47. Inhibition of RNA-directed DNA polymerase by aurintricarboxylic acid. Givens JF; Manly KF Nucleic Acids Res; 1976 Feb; 3(2):405-18. PubMed ID: 56743 [TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. Franchetti P; Cappellacci L; Grifantini M; Messini L; abu Sheikha G; Loi AG; Tramontano E; de Montis A; Spiga MG; La Colla P J Med Chem; 1994 Oct; 37(21):3534-41. PubMed ID: 7523675 [TBL] [Abstract][Full Text] [Related]
49. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. He Y; Chen F; Yu X; Wang Y; De Clercq E; Balzarini J; Pannecouque C Bioorg Chem; 2004 Dec; 32(6):536-48. PubMed ID: 15530994 [TBL] [Abstract][Full Text] [Related]
50. Effect of Evans blue and trypan blue on syncytia formation and infectivity of human immunodeficiency virus type I and type II in vitro. Pal R; Mumbauer S; Hoke G; Larocca R; Myers C; Sarngadharan MG; Stein CA AIDS Res Hum Retroviruses; 1991 Jun; 7(6):537-43. PubMed ID: 1718343 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Matsuno H; Kozawa O; Niwa M; Uematsu T Circulation; 1997 Aug; 96(4):1299-304. PubMed ID: 9286962 [TBL] [Abstract][Full Text] [Related]
52. Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Artico M; Silvestri R; Stefancich G; Massa S; Pagnozzi E; Musu D; Scintu F; Pinna E; Tinti E; La Colla P Arch Pharm (Weinheim); 1995 Mar; 328(3):223-9. PubMed ID: 7539250 [TBL] [Abstract][Full Text] [Related]
53. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997 [TBL] [Abstract][Full Text] [Related]
55. Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Tanaka H; Baba M; Ubasawa M; Takashima H; Sekiya K; Nitta I; Shigeta S; Walker RT; De Clercq E; Miyasaka T J Med Chem; 1991 Apr; 34(4):1394-9. PubMed ID: 2016715 [TBL] [Abstract][Full Text] [Related]
56. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. Joao HC; De Vreese K; Pauwels R; De Clercq E; Henson GW; Bridger GJ J Med Chem; 1995 Sep; 38(19):3865-73. PubMed ID: 7562918 [TBL] [Abstract][Full Text] [Related]
57. Redox process is crucial for inhibitory properties of aurintricarboxylic acid against activity of YopH: virulence factor of Yersinia pestis. Kuban-Jankowska A; Sahu KK; Niedzialkowski P; Gorska M; Tuszynski JA; Ossowski T; Wozniak M Oncotarget; 2015 Jul; 6(21):18364-73. PubMed ID: 26286963 [TBL] [Abstract][Full Text] [Related]
58. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437 [TBL] [Abstract][Full Text] [Related]
59. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528 [TBL] [Abstract][Full Text] [Related]